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Background: Acute mountain sickness (AMS) is a common disabling condition in
individuals experiencing high altitudes, which may progress to life-threatening high
altitude cerebral edema. Today, no established biomarkers are available for prediction the
susceptibility of AMS. MicroRNAs emerge as promising sensitive and specific biomarkers
for a variety of diseases. Thus, we sought to identify circulating microRNAs suitable for
prediction the susceptible of AMS before exposure to high altitude.
Methods: We enrolled 109 healthy man adults and collected blood samples before
their exposure to high altitude. Then we took them to an elevation of 3648m for 5
days. Circulating microRNAs expression was measured by microarray and quantitative
reverse-transcription polymerase chain reaction (qRT-PCR). AMS was defined as Lake
Louise score ≥3 and headache using Lake Louise Acute Mountain Sickness Scoring
System.
Results: A total of 31 microRNAs were differentially expressed between AMS
and Non-AMS groups, 15 up-regulated and 16 down-regulated. Up-regulation of
miR-369-3p, miR-449b-3p, miR-136-3p, and miR-4791 in patients with AMS compared
with Non-AMS individuals were quantitatively confirmed using qRT-PCR (all, P < 0.001).
With multiple logistic regression analysis, a unique signature encompassing miR-369-3p,
miR-449b-3p, and miR-136-3p discriminate AMS from Non-AMS (area under the curve
0.986, 95%CI 0.970–1.000, P < 0.001, LR+: 14.21, LR–: 0.08). This signature yielded
a 92.68% sensitivity and a 93.48% specificity for AMS vs. Non-AMS.
Conclusion: The study here, for the first time, describes a signature of three circulating
microRNAs as a robust biomarker to predict the susceptibility of AMS before exposure
to high altitude.
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INTRODUCTION
There are three main highland regions of the world that support large populations, including the
Tibetan plateau and Himalayan valleys, the Andes of South America, and the Ethiopian highlands.
With the development of economy and tourism, the number of individuals who ascended to high
altitude for a variety of reasons is increasing. Acute mountain sickness (AMS) is a public health
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problem of persons who acutely ascended to high altitude with
an elevation more than 2500m (Hackett et al., 1976; MacInnis
et al., 2013; Waeber et al., 2015). It may occur as early as 6–
24 h following ascent (Wright et al., 2008). The primary clinical
manifestation of AMS is a combination of several symptoms,
such as headache, anorexia, dizziness, malaise, nausea, and
sleep disturbance (Bärtsch and Swenson, 2013). Among these
symptoms, headache is the cardinal symptom of AMS and is
essential to diagnose AMS according to Lake Louise Scoring
System (LLS; Roach et al., 1993). LLS is a simple and widely
accepted tool for AMS assessment (Maggiorini et al., 1998),
which was created at the Hypoxia Symposium in 1991 and later
modified at the following Hypoxia Symposium in 1993. The
LLS encompasses two parts, a self-report questionnaire including
five symptoms (headache, gastrointestinal symptoms, dizziness,
and difficulty sleeping) and a clinical assessment comprising
three physical examination findings (alteredmental status, ataxia,
and peripheral edema). Severe AMS could make persons to be
incapacitating during the period of exposure to high altitude and,
more seriously, developed to high altitude cerebral edema which
is a life-threatening form of acute altitude illness (Basnyat and
Murdoch, 2003).
Given the high incidence of AMS among travelers and
its deleterious effect on health, identifying those susceptible
to the disorder would be useful as it would assist in the
development of preventive strategies for a given individual. By
far several prediction tools have been proposed, including cold
pressor test (Kovtun and Voevoda, 2013), heart rate variability
(Koehle et al., 2010; Karinen et al., 2012), and lung functions
(Zhou et al., 2004). All these tools detected the physiological
parameters of body, which were convenient and have low cost.
Recently, there was several studies focus on gene features in the
screening susceptibility of AMS (Ding et al., 2011). Although,
the parameters measured by those above tools present significant
association with the risk of AMS. The low sensitivity and
specificity limited the use of those simple sea level tests (Song
et al., 2013) and gene polymorphism detection method (Ding
et al., 2011).
MicroRNAs are small (∼22-nt long), noncoding,
single-stranded RNAs that regulate gene expression post-
transcriptionally in various physiological and pathophysiological
cellular processes such as proliferation (Lenkala et al., 2014),
differentiation (Shivdasani, 2006), metabolism (Dumortier et al.,
2013), and apoptosis (Su et al., 2015). In recent years, researchers
have found that microRNAs are also present in different body
fluids, the one in blood refer to circulating microRNA (Weber
et al., 2010). Circulating microRNAs are remarkably stable
and can be specific to certain physiological and pathological
conditions and are accessible to analysis through relatively
non-invasive methods (Mitchell et al., 2008). The significant
differences in their expression have been described in a wide
array of various diseases, although their physiological functions
Abbreviations: AMS, acute mountain sickness; qRT-PCR, quantitative reverse-
transcription polymerase chain reaction; LLS, Lake Louise Scoring System; AUC,
area under the receiver-operating characteristic curve; LR, likelihood ratio; NO,
nitric oxide; GO, gene ontology.
remained unknown (Ai et al., 2010; Moussay et al., 2011; Roth
et al., 2011).
Therefore, in the present study, we performed miRCURYTM
LNA Array (v.18.0) (Exiqon) screening, followed by data
validation with quantitative reverse-transcription polymerase
chain reaction (qRT-PCR) to evaluate plasma microRNA profiles
of individuals before exposure to high altitude to predict the
susceptibility of AMS. Interestingly, our data indicated that a
signature combined with circulating microRNAs miR-369-3p
(MIMAT0000721), miR-449b-3p (MIMAT0009203), and miR-
136-3p (MIMAT0004606) provided substantial AMS prediction.
METHODS AND MATERIALS
Participants
This study protocol was approved by the Ethics Committee
of third Military Medical University, China, in accordance
with the Declaration of Helsinki, and all individuals
provided written informed consent before entry. Excluding
individuals with a history of smoking and high altitude
travel, 109 adult health volunteers aged 17–35 years
whose primary residence was at an elevation of 1000m
or lower. Among them, 22 individuals were randomly
selected for microRNA array screening, while the
remaining 87 constituted the validation set with qRT-PCR
method.
Ascent and Blood Samples Collection
All participants were driven from Chongqing (elevation, 200 m),
China, before ascent. After a 3 day rest, they acutely ascended
to Lhasa (elevation, 3648 m), China, by train within 48 h, where
they remained for 5 days. Blood samples were collected in EDTA
tubes using standard operating procedures in the morning before
departure.
During the investigation, all volunteers had the same diet
and were required to abstain from strenuous activity to
ensure a similar level of physical activity. The investigators
continuously monitored the individuals for evidence of high
altitude pulmonary edema or high altitude cerebral edema
according to the specific clinical manifestations of these
diseases (Hackett and Roach, 2004; Pennardt, 2013). Immediate
evacuation and treatment with oxygen were available for such an
occurrence.
TABLE 1 | Primers used for qRT-PCR verification of differently expressed
circulating microRNAs.
microRNA Forward primer Reverse primer
miR-369-3p CAATGGAAATCGAATAATA
CATGG
TATGCTTGTTCTCGTCTCTGTGTC
miR-449b-3p CGCGCCAGCCACAACTAC TATGGTTGTTCACGACTCCTTCAC
miR-136-3p CGGCGCATCATCGTCTCA TATGGTTGTTCACGACTCCTTCAC
miR-4791 CGCGGCGCTGGATATGA TATGGTTGTTCACGACTCCTTCAC
cel-miR-39 ATATCATCTCACCGGGTGT
AAATC
TATGGTTTTGACGACTGTGTGAT
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Measurements
We measured main parameters, including blood
pressure, heart rate, and blood oxygen saturation, prior
to departure and successive 5 days after exposure
to high altitude. AMS was diagnosed using the LLS.
Self-report questionnaire of LLS were recorded prior
to departure and at each day during high altitude
exposure (5 days). Meanwhile, the clinical assessment
was done by our accompanied doctors. As per the
Lake Louise Consensus Group, individuals with a score
of three points or greater on the AMS self-report
questionnaire alone (including a headache score ≥ 1), or in
combination with the clinical assessment score designated
as AMS.
RNA Isolation and microRNA Array
Analysis
According to manufacturers’ instructions, total RNA was isolated
using TRIzol (Invitrogen) and purified with RNeasy mini
kit (QIAGEN). RNA quality and quantity were measured
on a NanoDrop spectrophotometer (ND-1000, Nanodrop
Technologies) and listed in Supplementary Table 1. After
quality control, the miRCURYTM Hy3TM/Hy5TM Power labeling
kit (Exiqon, Vedbaek, Denmark) was used according to
the manufacturer’s guideline for microRNA labeling. After
hybridized Hy3TM-labeled samples on a miRCURYTM LNA
Array (v.18.0) (Exiqon) and washed slides several times with
a Wash buffer kit (Exiqon), the slides were scanned on an
Axon GenePix 4000B microarray scanner (Axon Instruments,
FIGURE 1 | Trial flow diagram. AMS, acute mountain sickness; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; LLS, Lake Louise Scoring
System; BP, blood pressure; HR, heart rate; SpO2, oxygen saturation.
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Foster City, CA). Scanned images were then imported into
the GenePix Pro 6.0 software (Axon) for grid alignment and
data extraction. Replicated microRNAs were averaged, and
probes with intensities ≥30 in all samples were selected for
normalization. Detailed instructions were as previously described
(Liu et al., 2016).After normalization, significantly differentially
expressed microRNAs between the two groups were identified
using Fold change and P-value cutoffs of 2 and 0.05, respectively.
Quantitative Reverse-Transcription
Polymerase Chain Reaction (qRT-PCR)
For qRT-PCR, a synthetic Caenorhabditis elegans microRNA,
cel-miR-39 (Qiagen, Valencia, CA, USA), was added to plasma
samples as a control prior to RNA extraction. Total RNA
was extracted from 200 µL individual plasma samples with a
miRNeasy extraction kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions. RNA (6 µl) was reverse
transcribed into cDNA (in a final volume of 10µl) using a reverse
transcription kit (GenePharma, Shanghai, China). Subsequently,
quantitative real-time PCR was performed on an iQTM5 Real-
Time PCR Detection System (Bio-Rid, USA) using SYBR Green.
The primers used for qRT-PCR are listed in Table 1. Relative
microRNA levels were determined by the 2−1CT method.
Identifying Potential Biological Relevance
of microRNA Signature
To explore the potential biological relevance of microRNAs
signature, we predicted target genes of microRNAs usingmicroT-
CDS v5.0 (Paraskevopoulou et al., 2013) and TarBase v7.0
(Vlachos et al., 2015a). microT-CDS is an algorithm which is
specifically trained on a positive and a negative set of microRNA
recognition elements located in both the 3′-UTR and CDS
regions, while TarBase is the largest available manually curated
target database, indexing 9–250-fold more entries than any other
available database. Both of them are associated with the latest
miRBase version (v21) (Akhtar et al., 2016). Gene ontology
(GO) enrichment analysis was performed for target genes using
DIANA-miRPath v3. 0 which deciphers microRNA function with
experimental support (Vlachos et al., 2015b). Network between
microRNAs and target genes was constructed by Cytoscape v3.4.0
(Cline et al., 2007).
Statistical Analysis
Normality was assessed for all datasets by the Shapiro-Wilk’s test.
Then, independent t-test or Mann-Whitney U-test was carried
out to assess baseline differences between AMS and non-AMS
individuals. Comparison of the vitals mean difference between
AMS and non-AMS groups using the two-way mixed ANOVA.
Receiver operating characteristic curves were analyzed to assess
specificity and sensitivity of single-plasma microRNAs and their
combination using multiple logistic regression analysis. The
optimal diagnostic point of the microRNAs was assessed at cut-
off values with the largest Youden’s index. To investigate the
clinical impact of our signature microRNAs, we have chosen
the likelihood ratio (LR) in addition to classical test parameters-
sensitivity and specificity, because it combines information
of both. Odds ratio per standard deviation was calculated
by logistic regression analysis. Areas under the receiver-
operating characteristic curves (AUCs) were evaluated using
Swets classification (Gasparini et al., 2015): AUC = 0.5, no
diagnostic value; 0.5 < AUC < 0.7, accuracy to only a small
degree; 0.7 < AUC < 0.9, fair accuracy; 0.9 < AUC ≤ 1, high
accuracy.
Statistical analyses were performed with the R software
(version 3.2.3, R Foundation for Statistical Computing, Vienna,
Austria) with package “OptimalCutpoints” (López-Ratón et al.,
2014), IBM SPSS Statistics 19 (SPSS, Chicago, IL, USA, and
GraphPad Prism 5. The following values were considered
significant: P < 0.05(∗) and P < 0.01(∗∗).
RESULTS
Clinical Manifestation of All Individuals
The trail flow diagram is shown in Figure 1. Assessed by LLS,
13 individuals were diagnosed as AMS and 9 as Non-AMS in
microarray assay, while 41 volunteers were designated as AMS
and 46 as Non-AMS in qRT-PCR test. In total, the morbidity of
AMS is 49.5%. Respectively, there is no significant difference of
age betweenAMS group andNon-AMS individuals inmicroRNA
array screening set (23 ± 2.5 vs. 26 ± 6.5, P = 0.071) and qRT-
PCR assay set (22 ± 3.5 vs. 22 ± 4.0, P = 0.081), as well as body
mass index between AMS and Non-AMS groups (microRNA
array screening set: 21 ± 2.5 vs. 22 ± 3.0, P = 0.475; qRT-
PCR assay set: 22 ± 2.0 vs. 21 ± 4.0, P = 0.370; Table 2). After
exposure to high altitude, oxygen saturation of all individuals
significantly decreased, while heart rate significantly increased.
TABLE 2 | Characteristics of subjects.
Characteristics AMS Non-AMS P-values
microRNAS ARRAY SCREENING SET (n = 22)
Age (Year)
Median ± IQR* 23 ± 2.5 26 ± 6.5 0.071
Range 24–32 24–35
Sex
Male 13 9
Female 0 0
BMI* (kg/m2)
Median ± IQR* 21 ± 2.5 22 ± 3.0 0.475
Range 20–25 19–26
qRT-PCR ASSAY SET (n = 87)
Age (Year)
Median ± IQR* 22 ± 3.5 22 ± 4.0 0.081
Range 17–27 17–26
Sex
Male 41 46
Female 0 0
BMI* (kg/m2)
Median ± IQR* 22 ± 2.0 21 ± 4.0 0.370
Range 18–25 18–26
*IQR, interquartile range; BMI, body mass index.
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However, only on the third day after exposure to high altitude,
heart rate of AMS group was higher than Non-AMS individuals
(Supplementary Table 2).
MicroRNA Array and Validation of
microRNAs
MicroRNA array screening revealed that 31 microRNAs
were differentially expressed between AMS and Non-AMS
groups, 15 up-regulated and 16 down-regulated (Figure 2A).
Among them, miR-369-3p, miR-449b-3p, miR-136-3p, and
miR-4791 (MIMAT0019963) (all Fold changes > 5) were the
most significantly up-regulated microRNAs in the AMS group
compared with Non-AMS individuals. All the four microRNAs
were considered for further validation with qRT-PCR
assay.
Consistently, miR-369-3p, miR-449b-3p, miR-136-3p, and
miR-4791 (all P < 0.001) were significantly up-regulated in AMS
patients compared to Non-AMS individuals, using cel-miR-39 as
normalization control, within qRT-PCR test (Figure 2B).
MicroRNA Signature for the Identification
of Patients with Acute Mountain Sickness
The area under the curve (AUC) of miR-369-3p, miR-449b-
3p, miR-136-3p, and miR-4791 was 0.859, 0.847, 0.724, and
0.766, respectively (Figure 3,Table 3). Among them,miR-369-3p
present the highest accuracy for discrimination AMS from Non-
AMS individuals. However, the AUC was <0.850 for the remind
single-microRNA to predict AMS.
Combination of markers could improve accuracy in disease
diagnosis (Pepe and Thompson, 2000). So we performed
receiver operating characteristic curves for combination of
miR-369-3p, miR-449b-3p, miR-136-3p, and miR-4791 with
Logistic Regression analysis. A binomial logistic regression was
performed to ascertain the effects of miR-369-3p, miR-449b-3p,
miR-136-3p, and miR-4791 on the likelihood that participants
have AMS. Of the four predictor variables only three were
statistically significant: miR-369-3p, miR-449b-3p, and miR-136-
3p (Supplementary Table 3). Therefore, miR-4791 was excluded
from the logistic regression model.
The logistic regression model for miR-369-3p, miR-449b-3p,
and miR-136-3p was statistically significant, χ2(3) = 95.616, P
< 0.001. The model explained 89.0% (Nagelkerke R2) of the
variance in AMS and correctly classified 94.3% of cases. All
predictor variables were statistically significant (Supplementary
Table 4). Notably, the combination of miR-369-3p, miR-
449b-3p, and miR-136-3p resulted in a robustly increased
AUC (0.986, 95%CI 0.970–1.000; LR+: 14.21; LR−: 0.08),
leading to a signature for the prediction of AMS (Figure 4).
Accordingly, despite the single-microRNA cut-off values between
AMS and Non-AMS (>0.038 for miR-369-3p, >29.602 for
miR-449b-3p, and >0.045 for miR-136-3p; Table 3), a global
cut-off value of >0.110 for the signature of miR-369-3p,
miR-449b-3p, and miR-136-3p combination increased the
diagnostic power to a 92.68% sensitivity and a 93.48%
specificity.
FIGURE 2 | Circulating microRNAs expression profile was different
between acute mountain sickness (AMS) and non-acute mountain
sickness (Non-AMS) groups. (A) Comparisons of all microRNAs in
microarray analysis of RNA isolated from plasma of AMS and Non-AMS
groups. The volcano plot displays the relationship between fold-change and
significance using a scatter plot view. The red points in the plot represent the
differentially expressed microRNAs with statistical significance. (B) Results of
the quantitative reverse-transcription polymerase chain reaction of the
miR-369-3p, miR-449b-3p, miR-136-3p, and miR-4791 expression (AMS, n
= 41; Non-AMS, n = 46).
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FIGURE 3 | ROC curve analysis for single microRNAs to discriminate acute mountain sickness patients from non-acute mountain sickness
individuals. AUC, area under curve.
TABLE 3 | Receiver operating characteristic curves of single-plasma microRNAs.
AUC 95% CI P-values OR per SD 95% CI Cut off Sensitivity (%) 95% CI Specificity (%) 95% CI LR+ LR−
AMS vs. Non-AMS
miR-369-3p 0.859 0.783–0.935 <0.001 62.586 8.032–487.699 >0.038 0.95 0.83–0.99 0.65 0.50–0.79 2.73 0.07
miR-449b-3p 0.847 0.765–0.929 <0.001 8.659 3.311–22.648 >29.602 0.71 0.54–0.84 0.87 0.74–0.95 5.42 0.33
miR-136-3p 0.724 0.617–0.831 <0.001 4.874 1.740–13.433 >0.045 0.54 0.37–0.69 0.83 0.69–0.92 3.08 0.56
miR-4791 0.766 0.666–0.867 <0.001 7.130 2.409–21.104 >0.091 0.73 0.57–0.86 0.70 0.54–0.82 2.40 0.39
AUC, area under curve; CI, confidence interval; LR+, positive likelihood ratio; LR–, negative likelihood ratio; OR per SD, odds ratio per standard deviation; AMS, acute mountain sickness.
Biological Relevance of microRNA
Signature
GO enrichment analysis for target genes of microRNA signature
revealed that cellular nitrogen compound metabolic process,
gene expression, neurotrophin TRK receptor signaling pathway,
biosynthetic process, and viral process were the top five GO
term over-represented in target genes of the microRNA signature
(Figure 5, Supplementary Table 5).
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FIGURE 4 | ROC curve analysis for the combination of three
microRNAs (miR-369-3p, miR-449b-3p, and miR-136-3p) resulting in
enhanced specificity and sensitivity to distinguish acute mountain
sickness patients from non-acute mountain sickness individuals (97.6,
93.4%, respectively). AUC, area under curve; LR, likelihood ratio.
DISCUSSION
The number of individuals who ascended to high altitude for
a variety of reasons is increasing. AMS which can progress to
high altitude cerebral edema is a common problem to them
(Honigman et al., 1993; Hackett and Roach, 2001; Karinen et al.,
2008). Speed of ascent (Hackett et al., 1976), previous history of
AMS (Schneider et al., 2002), obesity (Ri-Li et al., 2003), migraine
(Mairer et al., 2009), and so forth (Taylor, 2011) have been
identified as risk factors for AMS. However, the incidence of AMS
is different in individuals, families and populations because of
their different capacity to cope with high-altitude environments
(MacInnis et al., 2010). This study for the first time reports
a novel signature of three circulating microRNAs allowing to
distinguishing AMS from Non-AMS individuals before exposure
to high altitude.
Nowadays, there are many ways to prevent AMS through
non-pharmacologic and pharmacologic measures (Imray et al.,
2010). Providing time for the body to acclimatize to high altitude
is the single best way to prevent AMS (Beidleman et al., 2004;
Luks et al., 2014), but it is not impracticable to individuals
with urgent task. Pharmacologic prophylaxis is an appropriate
way for the majority of individuals; however, the adverse effect
of pharmaceutical products could impair the health of people
(Dumont et al., 2000). Thus, identifying individuals susceptible
to AMS would assist in the development of suitable preventive
strategies for a given individual.
The study here provided a more effective method to detect
individuals at risk of AMS with circulating microRNAs than
those used currently. The receiver operating characteristic curves
revealed that the power of diagnostic test for AMS with a
92.68% sensitivity and a 93.48% specificity. Although already
one microRNA could discriminate to AUC of 0.859 between the
different groups, this approach failed in appropriate LR. Only
the combination of three microRNAs managed to deliver an
increased discrimination (AUC 0.986) with a high positive LR in
accordance with a low negative LR.
The biological relevance of circulating microRNAs is now
regarded as a global, hormone-like functional molecule that
might allow regulation of gene expression across tissues
at a distance (Turchinovich et al., 2013). Here, we found
that the expression value of microRNA signature in AMS
susceptible individuals was significantly higher than AMS
resistant individuals. Its target genes more enriched in cellular
nitrogen compound metabolic process and neurotrophin TRK
receptor signaling pathway. Nitric oxide (NO), generated
through cellular nitrogen compound metabolic process, is a
major signaling and effector molecule mediating the body’s
response to hypoxia (Beall et al., 2012). The generation of high
levels of NO and circulating nitrogen oxide species promote the
adaptation of natives of Tibet and acclimatization of lowlanders
who exposure to high altitude via enabling greater blood flow
and oxygen delivery (Erzurum et al., 2007; Janocha et al.,
2011). Neurotrophin TRK receptor is high-affinity receptor of
brain-derived neurotrophic factor whose concentration will be
increased in human plasma after exposure to high altitude
(elevation: 3350 m) for 72 h (Helan et al., 2014). Prakash
and his colleagues confirmed that brain-derived neurotrophic
factor could induce NO generation in human pulmonary artery
endothelial cells via TRK receptor (Meuchel et al., 2011).
Previously studies affirm that high levels of NO are associated
with function benefits and the avoidance of illness (Janocha et al.,
2011). The higher expression value of microRNA signature in
AMS susceptible individuals will suppress the genes involved in
cellular nitrogen compound metabolic process and neurotrophin
TRK receptor signaling pathway, post-transcriptionally and
cause a low levels of NO and circulating nitrogen oxide species.
Thus, the blunt production of NO and circulating nitrogen oxide
species via microRNAs may be the biological underpinning of
AMS susceptible individuals who present a higher expression
level of the microRNA signature consisted of miR-369-3p, miR-
449b-3p, and miR-136-3p.
We demonstrated for the first time a unique signature of
circulating microRNAs to differentiate AMS from Non-AMS
individuals. However, these results need to be confirmed in a
large patient cohort to exclude potential bias. And only the young
health men were included in this study because they are the main
part of population who travel to high altitudes for recreation,
work, and pilgrimage. Therefore, further investigations in more
individuals, also including females, other races and ages, should
be obtained to affirm the performance of the signature proposed
here.
CONCLUSION
Here, we, for the first time, describe a signature of circulating
microRNAs for sensitive and specific identification of the
susceptibility of AMS before exposure to high altitude. This
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FIGURE 5 | Direct interaction network between microRNAs and target genes. The diamond nodes represent microRNAs, while circular nodes represent target
genes. Color of circular nodes represents the most enriched association with a top five GO biological process. GO, Gene ontology.
signature may hold great promise to become an important tool
for the prediction of AMS.
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